Huons to Distribute Imojev Japanese Encephalitis Vaccine in Korea — Eter News

Enriched Analysis 深度解析

Huons to Distribute Imojev Japanese Encephalitis Vaccine in KoreaHuons将在韩国经销Imojev日本脑炎疫苗

South Korean pharmaceutical company Huons has signed an exclusive agreement with Substipharm Biologics to distribute Imojev Japanese encephalitis vaccine in Korea. The deal follows Huons’ establishment of a dedicated vaccine division in March and the addition of five products to its portfolio, with the company planning to use its existing cold-chain and injectable-drug sales infrastructure.韩国制药公司Huons已与Substipharm Biologics签署独家协议，在韩国经销Imojev日本脑炎疫苗。该交易是在Huons于3月成立专门疫苗部门并将五款产品纳入产品组合之后达成的，公司计划利用现有冷链基础设施和注射药物销售网络进行分销。

Korea Biomedical Review 1 Oct 2026 2026年10月1日

55

Vaccine products added to portfolio新增疫苗产品数量

65.965.9

Share of cases among people aged 50 or older50岁及以上人群病例占比

01The Story新闻事实

South Korean pharmaceutical company Huons has signed an exclusive agreement with Substipharm Biologics to distribute Imojev Japanese encephalitis vaccine in Korea. The deal follows Huons’ establishment of a dedicated vaccine division in March and the addition of five products to its portfolio, with the company planning to use its existing cold-chain and injectable-drug sales infrastructure.韩国制药公司Huons已与Substipharm Biologics签署独家协议，在韩国经销Imojev日本脑炎疫苗。该交易是在Huons于3月成立专门疫苗部门并将五款产品纳入产品组合之后达成的，公司计划利用现有冷链基础设施和注射药物销售网络进行分销。

  • Huons signed an exclusive agreement with Substipharm Biologics to distribute Imojev in Korea.Huons与Substipharm Biologics签署了在韩国经销Imojev的独家协议。
  • Imojev is a live attenuated Japanese encephalitis vaccine for children aged 12 months and older and adults.Imojev是一款减毒活日本脑炎疫苗，适用于12个月及以上儿童和成人。
  • Under the approved schedule, children receive two doses and adults receive one dose.按照获批接种程序，儿童需接种两剂，成人接种一剂。
  • People aged 50 or older accounted for 65.9% of Japanese encephalitis cases reported in Korea over the past five years.过去五年韩国报告的日本脑炎病例中，50岁及以上人群占65.9%。
  • Huons established a dedicated vaccine division in March and added five vaccine products to its portfolio.Huons于3月成立了专门的疫苗部门，并将五款疫苗产品纳入其产品组合。

The agreement gives Huons a commercial route to expand its vaccine business while addressing demand for prevention of a disease that continues to be reported in Korea.这项协议为Huons扩展疫苗业务提供了商业渠道，同时回应了韩国持续报告日本脑炎病例所带来的预防需求。

024 Dimensions维度分析

Future signal前瞻信号

Huons’ vaccine-business expansionHuons扩大疫苗业务

The Imojev deal follows the creation of a dedicated vaccine division and the addition of five products, indicating a broader push beyond a single distribution agreement.Imojev交易是在Huons成立专门疫苗部门并增加五款产品之后达成的，显示其布局并不局限于单一分销协议。

Vaccine products added to portfolio新增疫苗产品数量

20262026年5 products

  • Huons established a dedicated vaccine division in March.Huons于3月成立了专门的疫苗部门。
  • Huons said it plans to continue expanding its vaccine portfolio.Huons表示计划继续扩大疫苗产品组合。
Cause因果关系

Existing infrastructure supports distribution现有基础设施支持疫苗分销

Huons plans to use its cold-chain infrastructure and injectable-drug sales network, allowing the agreement to build on capabilities already in its business.Huons计划利用现有冷链基础设施和注射药物销售网络，使这项协议能够建立在其既有业务能力之上。

  • Huons said it will use its existing cold-chain infrastructure to distribute Imojev.Huons表示将利用现有冷链基础设施分销Imojev。
  • The company also plans to use its injectable drug sales network in Korea.该公司还计划利用其在韩国的注射药物销售网络。
Stakeholder impact利益相关方

Disease burden is concentrated among older adults疾病负担集中于老年人群

Although Imojev is indicated for children and adults, Huons highlighted that people aged 50 or older represented most reported cases in Korea over the past five years.尽管Imojev适用于儿童和成人，Huons指出，过去五年韩国报告病例中的大多数来自50岁及以上人群。

Share of cases among people aged 50 or older50岁及以上人群病例占比

65.9 %65.9%

Past five years过去五年

  • Japanese encephalitis is mosquito-borne and can cause severe neurological complications.日本脑炎通过蚊虫传播，可能导致严重神经系统并发症。
  • There is no specific antiviral treatment, making vaccination a key preventive measure.目前没有针对该疾病的特异性抗病毒治疗，因此接种疫苗是重要的预防措施。
Historical context历史脉络

Cross-border manufacturing and commercialization跨境生产与商业化

Substipharm acquired Imojev in 2022 and later invested in a vaccine manufacturing facility in Bangkok, while its biologics unit is based in Geneva and Huons will handle Korean distribution.Substipharm于2022年收购Imojev，随后投资了位于曼谷的疫苗生产设施；其生物制品部门设在日内瓦，而Huons将负责韩国市场的分销。

  • Substipharm acquired Imojev in 2022.Substipharm于2022年收购Imojev。
  • Substipharm subsequently invested in a vaccine manufacturing facility in Bangkok, Thailand.此后，Substipharm投资了位于泰国曼谷的疫苗生产设施。

03Timeline时间线

  1. 2022 Substipharm acquired Imojev.Substipharm收购Imojev。
  2. 2026-03 Huons established a dedicated vaccine division.Huons成立专门的疫苗部门。
  3. 2026-10-01 Huons announced its exclusive Korea distribution agreement with Substipharm Biologics.Huons宣布与Substipharm Biologics达成韩国市场独家分销协议。

Key takeaway核心结论

Huons is using an exclusive Imojev distribution agreement and its existing commercial infrastructure to build a larger vaccine business in Korea.Huons正借助Imojev独家分销协议和现有商业基础设施，在韩国建立更大的疫苗业务。

04What to Watch后续关注

  1. How Huons deploys its cold-chain and injectable-drug sales network for the Korean rollout of Imojev.Huons将如何利用冷链和注射药物销售网络在韩国推广Imojev。
  2. Whether Huons adds further vaccine products as it continues expanding its portfolio.Huons在继续扩大产品组合的过程中是否会增加更多疫苗产品。
  3. The distribution implications of Substipharm’s vaccine manufacturing investment in Bangkok.Substipharm在曼谷的疫苗生产投资将对分销产生何种影响。

05Uncertainties不确定因素

  • The source does not provide the agreement’s financial terms or duration.来源未披露协议的财务条款或期限。
  • The source does not state the planned launch date, distribution volume, or sales targets for Imojev in Korea.来源未说明Imojev在韩国的计划上市时间、分销数量或销售目标。

06Sources信息来源

  1. Huons signs Korea distribution deal for Japanese encephalitis vaccine Imojev < Pharma < Article - Korea Biomedical ReviewHuons signs Korea distribution deal for Japanese encephalitis vaccine Imojev < Pharma < Article - Korea Biomedical Review Korea Biomedical Review · 2026-10-01

Share this analysis 分享此深度分析

X Facebook LinkedIn WhatsApp